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Abstract The effect of the coating of ovalbumin-reconstituted 
liposomes with various oligosaccharides on their immunogenicity 
was investigated in mice. The coating of liposomes with oligoman- 
nose or yeast mannan drastically enhanced their ability to induce 
an ovalbumin-specific delayed-type footpad swelling response 
with a peak at 24 to 48 h post-challenge. Among various oligosac- 
charides tested, only those with mannose residue at the non- 
reducing termini manifested the activity when applied to li- 
posomes. Since such oligosaccharides are ubiquitously found in 
the body, these results suggested the usefulness of oligomannose- 
coated liposomes as a safe adjuvant for the induction of cell- 
mediated immunity. 
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1. Introduction 
Cell-mediated immunity (CMI) including delayed-type hy- 
persensitivity (DTH) and cytotoxic T-lymphocyte responses is 
implicated to be deeply involved in protection against such 
pathogens as human immunodeficiency virus [ 11, bovine leuke- 
mia virus [2], Leishmania major [3] Mycobacterium leprae [4] 
and Treponema pallidurn [5]. Thus, activation of the cell-medi- 
ated, rather than the antibody-mediated, arm of the immune 
system is considered to be required in a vaccine against these 
pathogens [6]. The only adjuvant available at present to the 
human is alum adjuvant made of aluminum hydroxide or alu- 
minum phosphate. This adjuvant, however, induces a poor 
CM1 response, if any at all. In order to design an adjuvant 
which is able to stimulate effective CM1 and is applicable to the 
human, we have undertaken a series of experiments to study 
the adjuvant activity of liposomes coated with oligosaccharides 
from the following reasons: (i) The surface of various infectious 
agents such as viruses [7], bacteria [8], yeast [9] and protozoa 
*Corresponding author. AGENE Research Institute, Co. Ltd. 200 
Kajiwara, Kamakura Kanagawa 247, Japan. Fax: (81) (467) 48 6595. 
Abbreviations: CMI, cell-mediated immunity; DTH, delayed-type hy- 
persensitivity; OVA, ovalbumin; DPPC, dipalmitoylphosphati- 
dylcholine; DPPE, dipalmitoylphosphatidylethanolamine; Mal5, man- 
nopentaose; IsoMal5, isomaltopentaose; LamiS, laminaripentaose; 
GlcNAc5, penta-N-acetylchitopentaose; Man5, mannopentaose; 
Man3, mannotriose; Man2, mannobiose; Manl, mannose. 
[lo] is covered with carbohydrate moieties including those rich 
in mannose, and it is possible that the immune system employs 
these chemical structures for its activation. (ii) Noguchi et al. 
[l l] reported that liposomes coated with yeast mannan induced 
a cytotoxic T-lymphocyte response against a virus-related pro- 
tein reconstituted in them, although mannan is considered not 
to be suitable for practical use since it is immunogenic and toxic 
[ 12,131. In the present study, liposomes reconstituted with oval- 
bumin (OVA) as a model antigen were coated with various 
oligosaccharides ubiquitously found in the human body or with 
mannan as a reference and their immunogenicity was studied 
in terms of the induction of DTH responses. 
2. Materials and methods 
Female inbred Balb/c mice of 6-week old were obtained from Charles 
River Japan, Inc. (Yokohama), and were used at the ages of 7-12 weeks 
old. 
Maltopentaose (Ma15), isomaltopentaose (IsoMalS), laminaripen- 
taose (LamiS), penta-N-acetylchitopentaose (GlcNAc5) and mannose 
(Manl) were purchased from Seikagaku Corporation, mannopentaose 
(ManS), mannotriose (Man3) and mannobiose (Man2) were from Dex- 
tra Laboratories Ltd. and high mannose-type oligosaccharides (RN) 
were prepared by hydrazinolysis from bovine pancreatic ribonuclease 
B as described previously [14]. The detailed chemical structure of these 
oligosaccharides is shown in Fig. 1. Mannan-cholesterol (Cholesterol- 
AECM Mannan) was obtained from Dojin Laboratories (Kumamoto), 
dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidyl- 
ethanolamine (DPPE) and cholesterol from Nichiyu Liposome Co. Ltd. 
(Tokyo), and OVA from Wako Purechem. Inc. Ltd. (Osaka). 
Neoglycolipids were constructed from DPPE and oligosaccharides 
listed in Fig. 1 as reported previously [15]. Liposomes (multilamellar 
vesicles) reconstituted with OVA were prepared with DPPC and 
cholesterol (2 : 1 in mol) according to the modified method by Banghm 
et al. [16]. Liposomes were coated with mannan-cholesterol and various 
oligosaccharide-DPPE conjugates except for Manl-, Man2- and Man3- 
DPPE by incubating liposomes with one of these neoglycolipids at 4°C 
for 3 days. More than 95% of neoglycolipid was adsorbed to liposomes. 
Since Manl-, Man2- and Man3-DPPE conjugates were water-insolu- 
ble, they were added to the solution of cholesterol and DPPC dissolved 
in chloroform and methanol when liposomes were prepared. 
A DTH response was assessed by footpad swelling according to the 
method as previously reported [17]. The specific footpad swelling re- 
sponses were expressed as the difference between the thickness of right 
(challenged with OVA in alum adjuvant) and left (challenged with alum 
adjuvant alone) footpads. 
3. Results 
A preliminary experiment indicated that the coating of OVA- 
liposomes with mannan-cholesterol or ManS-DPPE signifi- 
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Fig. 1. Chemical structure of oligosaccharides used in the construction of various neoglycolipids. 
cantly augmented the immunogenicity of liposomes to induce 
a DTH response as assessed by footpad swelling in Balb/c mice. 
At first, we roughly determined following experimental condi- 
tions (data not shown). The optimal dose of liposomes ex- 
pressed as the amount of cholesterol was found to be between 
60 to 70 pug per mouse. If the amount of liposomes was fixed 
in these conditions, the footpad responses increased dose-de- 
pendently from 0.2 to 0.9 ,ug OVA per mouse, attainig a max- 
imal level at the above doses. Maximal levels of the effect of 
coating liposomes with neoglycolipids were observed at the 
dose of 10 pug per mouse or more for mannan-cholesterol, and 
20 lug per mouse or more for ManS-DPPE. Most experiments 
were done using enough amount of OVA or neoglycolipids. 
Mice were subcutaneously inoculated with OVA together 
with various adjuvant and the footpad swelling response was 
assessed by challenging the footpad with OVA 7 days later. Fig. 
2 shows the time course of footpad responses post-challenge. 
OVA-liposomes coated with either mannan-cholesterol or 
ManS-DPPE conjugate induced a remarkable DTH response 
with a peak around 48 h post-challenge (g and h). Position of 
the peak varied between 24 and 48 h depending on the experi- 
ment. Either Man5 or mannan-coated liposomes induced ap- 
parently stronger and longer-lasting DTH responses than OVA 
in Freund’s complete adjuvant (FCA) (d), while non-coated 
OVA-liposomes induced a weak response with a peak around 
12 h post-challenge (f), which was very similar to the response 
elicited by immunization of OVA in alum adjuvant (c). The 
immunization of OVA in saline induced only poor responses 
at 12, 24 and 48 h (b). Both non-immunized mice and those 
immunized with mannan-coated liposomes without OVA failed 
to give any significant response (a and e). These results formally 
excluded the possibility that the anti-OVA footpad swelling 
responses were the consequence of a cross-reaction between 
OVA and compounents of liposomes such as mannan, oligo- 
mannose or lipids. 
The time course of footpad responses between 4 and 18 days 
post-immunization was investigated with the following results 
(data not shown): (i) significant 24- or 48-h responses were 
induced as early as 4 days post-immunization by either ManS- 
or mannan-coated liposomes, and the responses were main- 
tained until or even increased by 18 days, and (ii) non-coated 
liposomes induced a weak temporal 12-h response on day 7 
post-immunization with virtually no response at 18 days when 
anti-OVA antibodies as assessed by enzyme-linked immuno- 
sorbent assay appeared. 
The histological profile of the footpad swelling responses 
revealed the following facts (data not shown): the skin lesions 
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Fig. 2. Footpad swelling responses after challenge with OVA. (a) Non- 
immunization, (b) OVA in saline, (c) OVA in alum adjuvant, (d) OVA 
emulsified in FCA (l;l), (e) mannan-coated liposomes without OVA 
(92 fig mannan-cholesterol per mouse), (f) OVA-liposomes, (g) man- 
nan-coated OVA-liposomes (92 fig mannan-cholesterol per mouse), 
(h) ManS-coated OVA-liposomes (186 pg ManS-DPPEImouse). The 
dose of OVA and that of liposomes expressed as the amount of cholest- 
erol were 8.5 ,ug and 70 pug per mouse, respectively. 
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of 24- and 48-h responses by mannan- or Man%coated li- 
posomes manifested infiltration by numerous mononuclear 
cells and fewer polymorphonuclear cells. The 12-h response 
lesion of non-coated liposomes, on the other hand, was charac- 
terized by mild infiltration by polymorphonuclear leukocytes 
with a relatively small number of mononuclear cells. 
Table 1 shows the effect of various neoglycolipids (artificial 
glycolipids) on the immunogenicity of OVA-liposomes: li- 
posomes were coated with one of these neoglycolipids and their 
ability to induce a 24-h DTH response was studied. Ma15 
DPPE was not effective, while IsoMalS-, LamiS- and GlcNAcS- 
DPPE tended to stimulate the immunogenicity but with effects 
which were not statistically significant (Exp. 1 of Table 1). 
RN-DPPE as well as ManS-DPPE were significantly effective 
(Exp. 2). Among the three neoglycolipids of Exp. 3, Man2- 
DPPE and Man3-DPPE revealed a significant effect. It is noted 
that the pyranose ring of mannose of Manl-DPPE is opened, 
which may be the reason why this compound was not effective. 
In conclusion, among various oligosaccharide-DPPE conju- 
gates tested, only those with mannose residues at the non- 
reducing termini were effective. 
4. Discussion 
The present study demonstrated that the coating of OVA- 
liposomes with oligomannose or mannan drastically aug- 
mented their immunogenicity to mount an OVA-specific DTH 
response (Fig. 2). DTH against a conventional protein antigen 
can be classified into tuberculin-type and Jones-Mote-type 
Table 1 
Effect of various neoglycolipids on the adjuvant activity of OVA-Ii- 
posomes 
Group Neoglycolipids OVA Animal Footpad swelling % 
number (x lo-* mm 
f SE.) 
Exp. 1 
4 
5 
6 
Exp. 2 
2 
3 
4 
Exp. 3 
1 
2 
3 
4 
5 
nothing - 6 
nothing + 6 
mannan-cholesterol + 5 
MalS-DPPE + 5 
IsoMalS-DPPE + 5 
LamiS-DPPE + 5 
GlcNAcS-DPPE + 5 
nothing + 5 18.9 ? 2.7 100* 
mannan-cholesterol + 5 58.1 f 5.6b 307 
ManS-DPPE + 5 41.9 f 1.5’ 253 
RN-DPPE + 5 35.3 f 3.1’ 188 
nothing (+DPPE) - 5 
nothing (+DPPE) + 5 
Man1 -DPPE + 5 
Man2-DPPE + 5 
Man3-DPPE + 5 
6.1 f 2.0 
18.4 f 4.9 
38.9 f 3.7” 
19.0 * 4.4 
23.5 f 3.3 
23.4 f 2.8 
27.2 f 5.4 
10.5 f 4.4 
14.9 f 3.9 
26.2 f 5.7 
32.9 f 3.4d 
32.0 + 1.9* 
36 
100* 
211 
103 
128 
127 
148 
70 
100* 
176 
221 
215 
*Group 2 of Exp. 1, group 1 of Exp. 2 and group 2 of Exp. 3 were used 
as a control (100). SE., standard error. “P < 0.05 against group 2, 
“P < 0.001 and ‘P < 0.005 against group 1, dp < 0.001 against group 2. 
Exp. 1: the doses of OVA and neoglycolipids were 2.1 pg and 200 pg 
per mouse. Exp. 2: the dose of OVA was 3.9 fig while the doses of 
mannan-cholesterol, ManS-DPPE and RN-DPPE were 70 pg, 197 pg 
and 76 pg per mouse, respectively. Exp. 3: the dose of OVA was 610 
pg per mouse. The mol ratio of DPPC and DPPE or DPPE conjugates 
added to liposome preparations was 10: 1 (see also section 2). DPPE 
was added to groups 1 and 2 (+DPPE) as a control. 
hypersensitivity in the human and guinea pig, although the 
difference is not always clear-cut [ 181. Jones-Mote-hypersensi- 
tivity is characterized by: (i) the peak response post-challenge 
appears earlier (24 h), (ii) immunity is temporal, that is, it 
disappears when antibody appears, (iii) polymorphonuclear 
cells and basophils (in the guinea pig) are the major cells infil- 
trating in the lesion. On the other hand in tuberculin-type 
hypersensitivity, (i) the peak post-challenge appears later (48 to 
72 h), (ii) the immunity is longer-lasting and (iii) mononuclear 
cells are the dominant infiltrating cells in the lesion. As judged 
from the above criteria, the 24- and 48-h responses in mice 
induced by ManS- and mannan-coated liposomes are consid- 
ered to correspond to tuberculin-type hypersensitivity in the 
human and guinea pig whereas the 12-h response by non-coated 
liposomes is very likely to be Jones-Mote-type hypersensitivity. 
The effect of carbohydrate on CM1 may have an evolution- 
ary background in the immune system. It is conceivable that 
the defense system of the body has established a refined mech- 
anism to recognize the carbohydrate structure of various infec- 
tious agents and employs it to activate the immune system. The 
mannose receptors of macrophages [19-211 may be one such 
mechanism: these receptors are known to bind molecules con- 
taining non-reducing terminal carbohydrates with the following 
order of potency: o-mannose = L-fucose > D-GlcNAc = o-glu- 
cose >> o-galactose. This order is roughly consistent with the 
present results that among the various neoglycolipids tested 
only those with mannose at the non-reducing termini rendered 
a statistically significant effect when applied to liposomes 
(Table 1). Further experiments, however, are necessary to clar- 
ify the sugar specificity. It is possible that the receptor-mannose 
interaction of oligomannose- or mannan-coated liposomes aug- 
mented the processing of OVA reconstituted in these li- 
posomes. In addition, the mannose residues may possess some 
other activity such as the stimulation of IL-12 release culminat- 
ing in the activation of T-lymphocytes. 
From practical standpoint of view, mannan is considered not 
to be suitable for adjuvant from the following reasons. First, 
mannan is known to be highly immunogenic: it can elicit anti- 
body and B-cell mitosis [12]. Second, mannan is toxic to mice 
when it is intravenously injected [13]. One main difference in 
chemical structure between mannan and Man5 is that mannan 
possesses different glycosidic linkages, far more branches, 
higher molecular weight, and, as a consequence, much larger 
clusters of non-reducing termini of mannose than Man5 does. 
In contrast, the structure of either Man5 or DPPE exists as part 
of natural components of the body and thus ManS-DPPE is 
thought to be neither immunogenic nor toxic. Therefore, Man5 
is considered to be superior to mannan in safety. The present 
experimental system of liposomes coated with various oligosac- 
charides has provided a tool for elucidation of the role of 
carbohydrate in the immune system and has paved the way for 
the design of a safe adjuvant with which to induce effective CMI. 
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